MDT

Medtronic Inc.

Healthcare


Presented:11/10/2014
Price:$68.99
Cap:$67.60B
Current Price:$89.84
Cap:$115.22B

Presented

Date11/10/2014
Price$68.99
Market Cap$67.60B
Ent Value$66.41B
P/E Ratio24.78x
Book Value$19.75
Div Yield1.7%
Shares O/S979.52M
Ave Daily Vol8,970,000
Short Int6.91%

Current

Price$89.84
Market Cap$115.22B
Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company serves hospitals, physicians, clinicians, and patients in approximately 140 countries. Medtronic, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota.

Publicly traded companies mentioned herein: Medtronic Inc. (MDT), Covidien (COV), AbbVie (ABBV) and Shire (SHP LN).

Highlights

Medtronic is in the midst of attempting to close the Covidien (COV) deal, which would create the premier medtech company globally, but some investors have become wary in recent weeks given the growing aversion to risks related to inversion deals. Medtronic appears highly compelling as a standalone, but exposure can be gained through shares of Covidien for investors willing to play the spread (a discount of about 8% currently on a gross basis). The deal should materially improve MDT’s growth profile, with the potential to grow the top line in the mid single digits; EBITDA in the high single digits; and EPS in the double digits.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.